title: Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program.
abstract: In the event of an influenza pandemic, vaccination will be the best method to limit virus spread. However, lack of vaccine biomanufacturing capacity means there will not be enough vaccine for the world's population. The U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) provides support to the World Health Organization to enhance global vaccine production capacity in developing countries. However, developing a trained workforce in some of those countries is necessary. Biomanufacturing is labor-intensive, requiring unique skills not found in traditional academic programs. Employees must understand the scientific basis of biotechnology, operate specialized equipment, and work in an environment regulated by good manufacturing practices (cGMP). Therefore, BARDA supported development of vaccine biomanufacturing training at Utah State University. The training consisted of a three-week industry-focused course for participants from institutions supported by the BARDA and WHO influenza vaccine production capacity building program. The curriculum was divided into six components: (1) biosafety, (2) cell culture and growth of cells in bioreactors, (3) virus assays and inactivation, (4) scale-up strategies, (5) downstream processing, and (6) egg- and cell-based vaccine production and cGMP. Lectures were combined with laboratory exercises to provide a balance of theory and hands-on training. The initial course included sixteen participants from seven countries including: Egypt, Romania, Russia, Serbia, South Korea, Thailand, and Vietnam. The participant's job responsibilities included: Production, Quality Control, Quality Assurance, and Research; and their education ranged from bachelors to doctoral level. Internal course evaluations utilized descriptive methods including surveys, observation of laboratory activities, and interviews with participants. Generally, participants had appropriate academic backgrounds, but lacked expertise in vaccine production. All participants acknowledged the utility of the training, and many expressed interest in receiving additional support to implement new practices at their home institutions.
authors: Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA. bart.tarbet@usu.edu
authors: E Bart
authors: EB
authors: Tarbet
authors: James T
authors: JT
authors: Dorward
authors: Craig W
authors: CW
authors: Day
authors: Kamal A
authors: KA
authors: Rashid
mesh_terms: D057191:Capacity Building / Q000379:methods / Q000458:organization & administration; D003479:Curriculum; D004496:Education, Continuing; D007252:Influenza Vaccines / Q000592:standards* / Q000600:supply & distribution; D011786:Quality Control; D013678:Technology, Pharmaceutical / Q000193:education* / Q000458:organization & administration; D014481:United States; D014483:United States Dept. of Health and Human Services
chemical_list: D007252:Influenza Vaccines